Development of real-time fluorescent reverse transcription loop-mediated isothermal amplification assay with quenching primer for influenza virus and respiratory syncytial virus.

DNA Primers / genetics Humans Influenza, Human / diagnosis Orthomyxoviridae / isolation & purification Respiratory Syncytial Virus Infections / diagnosis Respiratory Syncytial Virus, Human / isolation & purification Respiratory Tract Infections / diagnosis Reverse Transcriptase Polymerase Chain Reaction Sensitivity and Specificity Temperature
Influenza virus RT-LAMP assay Real-time Respiratory syncytial virus

Journal

Journal of virological methods
ISSN: 1879-0984
Titre abrégé: J Virol Methods
Pays: Netherlands
ID NLM: 8005839

Informations de publication

Date de publication:
05 2019
Historique:
received: 18 09 2018
revised: 31 01 2019
accepted: 28 02 2019
pubmed: 5 3 2019
medline: 7 3 2020
entrez: 5 3 2019
Statut: ppublish

Résumé

Influenza virus and respiratory syncytial virus cause acute upper and lower respiratory tract infections, especially in children and the elderly. Early treatment for these infections is thought to be important, so simple and sensitive detection methods are needed for use at clinical sites. Therefore, in this study, real-time reverse transcription loop-mediated isothermal amplification assays with quenching primer for influenza virus and respiratory syncytial virus were developed. Evaluation of a total of 113 clinical specimens compared to real-time RT-PCR assays showed that the novel assays could distinguish between the types and subtypes of influenza virus and respiratory syncytial virus and had 100% diagnostic specificity. The diagnostic sensitivity of each assay exceeded 85.0% and the assays showed sufficient clinical accuracy. Furthermore, positive results could be obtained in around 15 min using the novel assays in cases with high concentrations of virus. The developed assays should be useful for identifying influenza virus and respiratory syncytial virus cases not only in experimental laboratories but also in hospital and quarantine laboratories.

Identifiants

DOI: 10.1016/j.jviromet.2019.02.010 PMID: 30831121 PMC: PMC7113748
pubmed: 30831121
pii: S0166-0934(18)30472-5
doi: 10.1016/j.jviromet.2019.02.010
pmc: PMC7113748
pii:
doi:

Substances chimiques

DNA Primers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

53-58

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Références

Nucleic Acids Res. 2000 Jun 15;28(12):E63
pubmed: 10871386
N Engl J Med. 2015 Feb 26;372(9):835-45
pubmed: 25714161
J Mol Diagn. 2010 Jan;12(1):102-8
pubmed: 19948820
J Clin Virol. 2015 Apr;65:83-6
pubmed: 25766995
Environ Technol. 2016 Feb;37(4):478-485
pubmed: 26198662
Sci Rep. 2017 Jun 26;7(1):4253
pubmed: 28652587
Nucleic Acids Res. 2001 Mar 15;29(6):E34
pubmed: 11239011
Virol J. 2014 Aug 08;11:139
pubmed: 25103205
J Clin Virol. 2014 Sep;61(1):113-7
pubmed: 25034375
J Appl Microbiol. 2010 Nov;109(5):1724-32
pubmed: 20629802
Anal Biochem. 2001 Mar 1;290(1):89-97
pubmed: 11180941
N Engl J Med. 1997 Sep 25;337(13):874-80
pubmed: 9302301
J Virol Methods. 2014 Sep 1;205:110-5
pubmed: 24797457
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7797
pubmed: 2217213
Jpn J Infect Dis. 2014;67(6):469-75
pubmed: 25410563
J Clin Microbiol. 1997 Oct;35(10):2623-7
pubmed: 9316919
Diagn Microbiol Infect Dis. 2014 May;79(1):10-3
pubmed: 24582581
Clin Microbiol Rev. 2000 Jul;13(3):371-84
pubmed: 10885982
J Microbiol Methods. 2015 Dec;119:223-7
pubmed: 26554941
J Antimicrob Chemother. 2003 Jan;51(1):123-9
pubmed: 12493796
J Med Virol. 2011 Jan;83(1):10-5
pubmed: 21108334
J Virol Methods. 2013 Sep;192(1-2):18-24
pubmed: 23583488
Clin Infect Dis. 2012 May;54(10):1427-36
pubmed: 22495079
PLoS Negl Trop Dis. 2012;6(6):e1572
pubmed: 22745836
Anal Sci. 2001 Jan;17(1):155-60
pubmed: 11993654
Anal Biochem. 2003 Mar 1;314(1):77-86
pubmed: 12633605
Lancet. 2001 Oct 27;358(9291):1410-6
pubmed: 11705487
Biochem Biophys Res Commun. 2001 Nov 23;289(1):150-4
pubmed: 11708792
Mol Cell Probes. 2002 Jun;16(3):223-9
pubmed: 12144774
Nat Protoc. 2008;3(5):877-82
pubmed: 18451795
J Virol Methods. 2011 Jan;171(1):156-62
pubmed: 21029748
Pediatrics. 2003 Aug;112(2):363-7
pubmed: 12897288
J Med Virol. 2017 Sep;89(9):1574-1583
pubmed: 28332201
PLoS Negl Trop Dis. 2016 Feb 22;10(2):e0004472
pubmed: 26900929
J Med Virol. 2000 Jan;60(1):102-6
pubmed: 10568771

Auteurs

Ikuyo Takayama (I)

Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.

Mina Nakauchi (M)

Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.

Hitoshi Takahashi (H)

Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.

Kunihiro Oba (K)

Department of Pediatrics, Showa General Hospital, 8-1-1 Hanakoganei, Kodaira-shi, Tokyo 187-0002, Japan.

Shohei Semba (S)

Eiken Chemical Co. Ltd., 4-19-9 Taito, Taito-ku, Tokyo 110-8408, Japan.

Atsushi Kaida (A)

Division of Microbiology, Osaka Institute of Public Health, 8-34 Tojo-cho, Tennoji-ku, Osaka 543-0026, Japan.

Hideyuki Kubo (H)

Division of Microbiology, Osaka Institute of Public Health, 8-34 Tojo-cho, Tennoji-ku, Osaka 543-0026, Japan.

Shinji Saito (S)

Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.

Shiho Nagata (S)

Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.

Takato Odagiri (T)

Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan.

Tsutomu Kageyama (T)

Influenza Virus Research Center, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama-shi, Tokyo 208-0011, Japan. Electronic address: tkage@nih.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Sondes moléculaires › Sondes d'acide nucléique › Sondes d'ADN › Amorces ADN › Development of real-time fluorescent reverse...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Development of real-time fluorescent reverse...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Grippe humaine › Development of real-time fluorescent reverse...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Orthomyxoviridae › Development of real-time fluorescent reverse...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Mononegavirales › Infections à Paramyxoviridae › Infections à pneumovirus › Infections à virus respiratoire syncytial › Development of real-time fluorescent reverse...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Mononegavirales › Paramyxoviridae › Pneumovirinae › Pneumovirus › Virus respiratoires syncytiaux › Virus respiratoire syncytial humain › Development of real-time fluorescent reverse...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Development of real-time fluorescent reverse...
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Techniques d'amplification d'acides nucléiques › Réaction de polymérisation en chaîne › RT-PCR › Development of real-time fluorescent reverse...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Sensibilité et spécificité › Development of real-time fluorescent reverse...
questionsmedicales.fr › Environnement et santé publique › Environnement › Concepts météorologiques › Atmosphère › Temps (météorologie) › Température › Development of real-time fluorescent reverse...